Aaron Tachibana Sells 51,251 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 51,251 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,620,618.94. The trade was a 20.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Thursday, June 4th, Aaron Tachibana sold 40,000 shares of Personalis stock. The shares were sold at an average price of $12.01, for a total transaction of $480,400.00.
• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The shares were sold at an average price of $11.58, for a total value of $449,292.42.

Personalis Trading Up 3.4%

Shares of NASDAQ PSNL opened at $13.02 on Friday. Personalis, Inc. has a 12-month low of $3.84 and a 12-month high of $13.37. The company has a market cap of $1.36 billion, a PE ratio of -12.76 and a beta of 2.28. The stock has a 50 day simple moving average of $8.42 and a 200-day simple moving average of $8.29.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.48 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. Sell-side analysts forecast that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PSNL. Aberdeen Group plc increased its position in shares of Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after purchasing an additional 861,948 shares during the period. Oracle Investment Management Inc. bought a new position in Personalis during the third quarter valued at about $1,496,000. ARK Investment Management LLC boosted its stake in Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after buying an additional 802,268 shares in the last quarter. Howland Capital Management LLC grew its holdings in Personalis by 65.5% during the fourth quarter. Howland Capital Management LLC now owns 547,115 shares of the company’s stock worth $4,355,000 after acquiring an additional 216,442 shares during the period. Finally, D.A. Davidson & CO. acquired a new position in Personalis during the fourth quarter worth about $1,158,000. 61.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Morgan Stanley decreased their target price on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Finally, BTIG Research dropped their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Personalis presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.